Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug;31(7-8):289-290.
doi: 10.1007/s12471-023-01794-z. Epub 2023 Jul 25.

Should we offer preventive treatment to all carriers of PLN p.(Arg14del) variant? : Con: Do no harm to asymptomatic carriers

Pieter A Doevendans  1   2
Affiliations
Review

Should we offer preventive treatment to all carriers of PLN p.(Arg14del) variant? : Con: Do no harm to asymptomatic carriers

Pieter A Doevendans. Neth Heart J. 2023 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

P.A. Doevendans declares that he has no competing interests.

References

    1. Van Rijsingen IAW, van der Zwaag PA, Groeneweg JA, et al. Outcome in phospholamban R14del carriers: results of a large multicentre cohort study. Circ Cardiovasc Genet. 2014;7:455–465. doi: 10.1161/CIRCGENETICS.113.000374. - DOI - PubMed
    1. Van de Leur RR, Taha K, Bos MN, et al. Discovering and visualizing disease-specific electrocardiogram features using deep learning: proof-of-concept in phospholamban gene mutation carriers. Circ Arrhythm Electrophysiol. 2021;14:e009056. doi: 10.1161/CIRCEP.120.009056. - DOI - PMC - PubMed
    1. Taha K, Mast TP, Cramer MJ, et al. Evaluation of disease progression in arrhythmogenic cardiomyopathy: the change of echocardiographic deformation characteristics over time. JACC Cardiovasc Imaging. 2020 doi: 10.1016/j.jcmg.2019.08.014. - DOI - PubMed
    1. Eijgenraam TR, Boukens BJ, Boogerd CJ, et al. The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unreponsive to standard heart failure therapy. Sci Rep. 2020;10:9819. doi: 10.1038/s41598-020-66656-9. - DOI - PMC - PubMed
    1. De Brouwer R, Te Rijdt WP, Hoorntje ET, et al. A randomized controlled trial of eplerenone in asymptomatic phospholamban p.Arg14del carriers. Eur Heart J. 2023 doi: 10.1093/eurheartj/ehad292. - DOI - PMC - PubMed